RhumbLine Advisers’s Eledon Pharmaceuticals ELDN Stock Holding History

RhumbLine Advisers’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$147K	Buy	47,626 +3,009	+7%	+$7.09K	﹤0.01%	3253
2025 Q4	$67.4K	Sell	44,617 -8,947	-17%	-$21.3K	﹤0.01%	3581
2025 Q3	$139K	Sell	53,564 -2,486	-4%	-$7.27K	﹤0.01%	3388
2025 Q2	$152K	Buy	+56,050	New	+$168K	﹤0.01%	3375
2017 Q2	–	Sell	-197	Closed	-$27K	–	2932
2017 Q1	$27K	Buy	+197	New	+$28.9K	﹤0.01%	2838
2016 Q2	–	Sell	-70	Closed	-$64K	–	2992
2016 Q1	$64K	Buy	70 +3	+4%	+$2.94K	﹤0.01%	2949
2015 Q4	$94K	Buy	67 +5	+8%	+$8.71K	﹤0.01%	2962
2015 Q3	$104K	Buy	+62	New	+$128K	﹤0.01%	2940

Other funds holding ELDN

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $712M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

RhumbLine Advisers's ELDN Position: Q1 2026 in Review

RhumbLine Advisers increased its Eledon Pharmaceuticals (ELDN) stake by 6.7% in Q1 2026, buying an estimated $7.09K and bringing the position to 47,626 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #3253.

RhumbLine Advisers first reported a position in ELDN in Q3 2015 and has held it in 8 quarters since. The position peaked at $152K in Q2 2025. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

RhumbLine Advisers held 47,626 shares of Eledon Pharmaceuticals worth $147K as of Q1 2026.
RhumbLine Advisers bought 3,009 Eledon Pharmaceuticals shares in Q1 2026, an estimated $7.09K.
Eledon Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3253 holding.
RhumbLine Advisers first reported a position in Eledon Pharmaceuticals in Q3 2015 and has held it in 8 quarters since.
RhumbLine Advisers's Eledon Pharmaceuticals position peaked at $152K in Q2 2025.
121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.